Figure 1. PRISMA Diagram

Identification

Records identified through database searching
(n = 1488)

Additional records identified through other sources
(n = 26)

Screening

Records after duplicates removed
(n = 1148)

Records screened
(n = 1148)

Records excluded
(n = 1089)

Eligibility

Full-text articles assessed for eligibility
(n = 59)

Full-text articles excluded, with reasons
(n = 46)

Non-Relevant Randomization: 34

Single-Center Design: 4

Lifelong ADT Duration: 1

No Reported MFS Outcomes: 5

No IPD: 3

Included

Studies included in meta-analysis
(n = 13)

Figure 2. Forest Plots Derived from Frequentist Network Meta-Analysis of Treatment Strategy Impact on Survival Outcomes

A. Metastasis-Free Survival

Treatment	Reference: LDRT	HR	95%-CI	P-score
HDRT+LTADT		0.56	[0.39; 0.81]	0.92
LDRT+LTADT		0.60	[0.49; 0.73]	0.87
LDRT+STADT		0.82	[0.72; 0.95]	0.49
HDRT+STADT		0.82	[0.65; 1.03]	0.48
HDRT		0.97	[0.80; 1.18]	0.15
LDRT		1.00		0.08

B. Overall Survival

Treatment	Reference: LDRT	HR	95%-CI	P-score
HDRT+LTADT		0.59	[0.42; 0.84]	0.96
LDRT+LTADT		0.71	[0.61; 0.84]	0.81
HDRT+STADT		0.85	[0.69; 1.04]	0.50
LDRT+STADT		0.86	[0.77; 0.96]	0.47
HDRT		0.97	[0.82; 1.15]	0.16
LDRT		1.00		0.08

C. Biochemical Recurrence-Free Survival

| Treatment	Reference: LDRT	HR	95%-CI	P-score
HDRT+LTADT		0.33	[0.23; 0.46]	0.98
LDRT+LTADT		0.42	[0.34; 0.52]	0.80
HDRT+STADT		0.50	[0.40; 0.64]	0.61
LDRT+STADT		0.67	[0.57; 0.79]	0.39
HDRT		0.78	[0.64; 0.95]	0.21
LDRT		1.00		0.00

Figure 3. Predicted Treatment Rankings for Metastasis-Free Survival, Overall Survival, and Biochemical Recurrence-Free Survival